id	author	title	date	pages	extension	mime	words	sentence	flesch	summary	cache	txt
cord-336535-r3a57m57	Kohmer, Niko	Brief clinical evaluation of six high-throughput SARS-CoV-2 IgG antibody assays	2020-06-01		.txt	text/plain	1483	54	41	Focusing on IgG and total antibodies, we demonstrate the performance of four automated immunoassays (Abbott Architect™ i2000 (N protein-based)), Roche cobas™ e 411 analyzer (N protein-based, not differentiating between IgA, IgM or IgG antibodies), LIAISON®XL platform (S1 and S2 protein-based), VIRCLIA® automation system (S1 and N protein-based) in comparison two ELISA assays (Euroimmun SARS-CoV-2 IgG (S1 protein-based) and Virotech SARS-CoV-2 IgG ELISA (N protein-based)) and an in-house developed plaque reduction neutralization test (PRNT). The Euroimmun SARS-CoV-2 IgG ELISA (Euroimmun, Lübeck, Germany) and Virotech SARS-CoV-2 IgG ELISA (Virotech Diagnostics GmbH, Rüsselsheim, Germany; TABLE 1) were used, in an identical manner, according to the manufacturer's recommendation.	cache/cord-336535-r3a57m57.txt	txt/cord-336535-r3a57m57.txt
